NCT06601595View on ClinicalTrials.gov

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions

Inflammatory Bowel Disease (IBD)SpondylarthropathiesTNF-alpha Inhibitors

Interventions

DRUG

TNF inhibitors

tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease

DRUG

conventional ibd medical treatment

Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.

All Listed Sponsors

lead

Mohamed Nasr

OTHER

NCT06601595 - Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital | Biotech Hunter | Biotech Hunter